{Reference Type}: Case Reports
{Title}: Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.
{Author}: Posso-Osorio I;Vargas-Potes CJ;Mejía M;Cañas CA;
{Journal}: Clin Rheumatol
{Volume}: 42
{Issue}: 9
{Year}: 2023 Sep 18
{Factor}: 3.65
{DOI}: 10.1007/s10067-023-06612-w
{Abstract}: Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.